Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 3/2005

01.03.2005 | Original Article

Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial

verfasst von: Nanda C. Krak, R. Boellaard, Otto S. Hoekstra, Jos W. R. Twisk, Corneline J. Hoekstra, Adriaan A. Lammertsma

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Quantitative measurement of tracer uptake in a tumour can be influenced by a number of factors, including the method of defining regions of interest (ROIs) and the reconstruction parameters used. The main purpose of this study was to determine the effects of different ROI methods on quantitative outcome, using two reconstruction methods and the standard uptake value (SUV) as a simple quantitative measure of FDG uptake.

Methods

Four commonly used methods of ROI definition (manual placement, fixed dimensions, threshold based and maximum pixel value) were used to calculate SUV (SUV[MAN], SUV15 mm, SUV50, SUV75 and SUVmax, respectively) and to generate “metabolic” tumour volumes. Test–retest reproducibility of SUVs and of “metabolic” tumour volumes and the applicability of ROI methods during chemotherapy were assessed. In addition, SUVs calculated on ordered subsets expectation maximisation (OSEM) and filtered back-projection (FBP) images were compared.

Results

ROI definition had a direct effect on quantitative outcome. On average, SUV[MAN], SUV15 mm, SUV50 and SUV75, were respectively 48%, 27%, 34% and 15% lower than SUVmax when calculated on OSEM images. No statistically significant differences were found between SUVs calculated on OSEM and FBP reconstructed images. Highest reproducibility was found for SUV15 mm and SUV[MAN] (ICC 0.95 and 0.94, respectively) and for “metabolic” volumes measured with the manual and 50% threshold ROIs (ICC 0.99 for both). Manual, 75% threshold and maximum pixel ROIs could be used throughout therapy, regardless of changes in tumour uptake or geometry. SUVs showed the same trend in relative change in FDG uptake after chemotherapy, irrespective of the ROI method used.

Conclusion

The method of ROI definition has a direct influence on quantitative outcome. In terms of simplicity, user-independence, reproducibility and general applicability the threshold-based and fixed dimension methods are the best ROI methods. Threshold methods are in addition relatively independent of changes in size and geometry, however, and may therefore be more suitable for response monitoring purposes.
Literatur
1.
Dimitrakopoulou-Strauss A, Strauss LG, Heichel T, et al. The role of quantitative 18F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med 2002;43:510–8PubMed
2.
Avril N, Bense S, Ziegler SI, et al. Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med 1997;38:1186–91PubMed
3.
Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [18F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676–88PubMed
4.
Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology1999;213:521–5
5.
Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689–95PubMed
6.
Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin’s lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464–71PubMed
7.
Choi NC, Fischman AJ, Niemierko A, et al. Dose-response relationship between probability of pathologic tumour control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;54:1024–35CrossRefPubMed
8.
Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002;24:127–35CrossRefPubMed
9.
Weber WA, Ziegler SI, Thodtmann R, et al. Reproducibility of metabolic measurements in malignant tumours using FDG PET. J Nucl Med 1999;40:1771–7PubMed
10.
Lee JR, Madsen MT, Bushnel D, et al. A threshold method to improve standardized uptake value reproducibility. Nucl Med Commun 2000; 21:685–90
11.
Graham MM, Peterson LM, Hayward RM. Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 2000;7:647–55CrossRef
12.
Hunter GJ, Hamberg LM, Alpert NM, et al. Simplified measurement of deoxyglucose utilization rate. J Nucl Med 1996;37:950–5PubMed
13.
Kole AC, Nieweg OE, Pruim J, et al. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and l-[1-11C]tyrosine PET. J Nucl Med 1997;38:692–6PubMed
14.
Avril N, Dose J, Janicke F, et al. Metabolic characterization of breast tumours with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996;14:1848–57
15.
Nakamoto Y, Zasadny KR, Minn H, et al. Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-d-glucose. Mol Imaging Biol 2002;4:171–8CrossRefPubMed
16.
Chin BB, Lyengar S, Sabundayo BP, et al. Standardized uptake values in 2-deoxy-2-[18F]fluoro-d-glucose with positron emission tomography: clinical significance of iterative reconstruction and segmented attenuation compared with conventional filtered back projection and measured attenuation correction. Mol Imaging Biol 2002;4:294–300CrossRefPubMed
17.
Visvikis D, Cheze-LeRest C, Costa DC, et al. Influence of OSEM and segmented attenuation correction in the calculation of standardised uptake values for [18F]FDG PET. Eur J Nucl Med 2001;28:1326–35CrossRefPubMed
18.
Boellaard R, Krak NC, Hoekstra OS, et al. Effects of noise, image resolution and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004;45:1519–27PubMed
19.
Hoekstra CJ, Hoekstra OS, Stroobants SG, et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 2002;43:1304–09PubMed
20.
Boellaard R, van Lingen A, Lammertsma AA. Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic PET: quantitative characteristics and effects on kinetic modeling. J Nucl Med 2001;42:808–17PubMed
21.
Hoekstra CJ, Paglianiti I, Hoekstra OS, et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 2000;27:731–43
22.
Yang SN, Liang JA, Lin FJ, et al. Differentiating benign and malignant pulmonary lesions with FDG-PET. Anticancer Res 2001;21:4153–57PubMed
23.
Hubner KF, Buonocore E, Gould HR, et al. Differentiating benign from malignant lung lesions using “quantitative” parameters of FDG PET images. Clin Nucl Med 1996;21:941–9CrossRefPubMed
24.
Minn H, Zasadny KR, Quint LE, et al. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-d-glucose uptake at PET. Radiology 1995;196:167–73PubMed
25.
Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumours using FDG PET. J Nucl Med 1999;40:1771–7PubMed
26.
Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101–11PubMed
27.
Mankoff DA, Dunwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003;44:1806–14PubMed
28.
Jansson T, Westlin JE, Ahlstrom H, et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995;13:1470–7PubMed
29.
Zasadny KR, Kison PV, Fransis IR, et al. FDG-PET determination of metabolically active tumour volume and comparison with CT. Clin Pos Imaging 1998;1:123–9CrossRef
30.
Erdi YE, Mawlawi O, Larson SM, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer1997;15:2505–9
31.
Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773–82CrossRefPubMed
32.
Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995;36:1836–9PubMed
33.
Ramos CD, Erdi YE, Gonen M, et al. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med 2001;28:155–64CrossRefPubMed
34.
Etchebehere EC, Macapinlac HA, Gonen M, et al. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of 18«F-FDG PET. Q J Nucl Med 2002;46:122–30PubMed
35.
Lonneux M, Borbath I, Bol A, et al. Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction. Eur J Nucl Med 1999;26:591–8CrossRefPubMed
Metadaten
Titel
Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial
verfasst von
Nanda C. Krak
R. Boellaard
Otto S. Hoekstra
Jos W. R. Twisk
Corneline J. Hoekstra
Adriaan A. Lammertsma
Publikationsdatum
01.03.2005
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2005
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-004-1566-1

Weitere Artikel der Ausgabe 3/2005

European Journal of Nuclear Medicine and Molecular Imaging 3/2005 Zur Ausgabe

Original Article

Incidence of stunned, hibernating and scarred myocardium in ischaemic cardiomyopathy

Original Article

The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels

Controversies–For

Is whole-body FDG-PET valuable for health screening?

Image of the Month

ECG-triggered high-resolution positron emission tomography: a breakthrough in cardiac molecular imaging of mice

Erratum

Tetrahydrobiopterin restores impaired coronary microvascular dysfunction in hypercholesterolaemia

Original Article

Quantification of disease activity in patients undergoing leucocyte scintigraphy for suspected inflammatory bowel disease